Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au Thu, 08 Apr 2021 23:15:41 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence https://melanomaresearchvic.com.au/dutch-consortium-investigates-biomarker-to-identify-early-stage-melanoma-at-high-risk-of-recurrence Thu, 08 Apr 2021 07:47:43 +0000 https://melanomaresearchvic.com.au/?p=16565 Today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at high risk of disease-related fatality.

The post Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence appeared first on Melanoma Research Victoria.

]]>
Source: PR Newswire, February 2021

Today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at high risk of disease-related fatality. Approximately 90% of all melanoma patients are diagnosed with an early-stage melanoma (American Joint Classification on Cancer [AJCC] stage I/II), without any lymph node metastasis or distant metastasis at time of diagnosis. However, 41% of melanoma-related deaths, are these early-stage patients that are anticipated to have a good prognosis at their diagnosis.

READ THE ORIGINAL FULL ARTICLE

The post Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence appeared first on Melanoma Research Victoria.

]]>
New test to help fight deadly melanoma https://melanomaresearchvic.com.au/new-test-to-help-fight-deadly-melanoma Thu, 08 Apr 2021 07:38:15 +0000 https://melanomaresearchvic.com.au/?p=16563 Researchers from QIMR Berghofer Medical Research Institute have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.

The post New test to help fight deadly melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Medical Xpress, February 2021

Researchers from QIMR Berghofer Medical Research Institute have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.

Details about the test and the study are being published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

READ THE ORIGINAL FULL ARTICLE

The post New test to help fight deadly melanoma appeared first on Melanoma Research Victoria.

]]>
Dabrafenib plus trametinib improves relapse-free survival time in melanoma https://melanomaresearchvic.com.au/dabrafenib-plus-trametinib-improves-relapse-free-survival-time-in-melanoma Thu, 08 Apr 2021 07:31:23 +0000 https://melanomaresearchvic.com.au/?p=16561 Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.

The post Dabrafenib plus trametinib improves relapse-free survival time in melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Healio, February 2021

Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.

“Kaplan-Meier and Cox regression analyses have been used to assess adjuvant treatment effects based on time-to-event analyses,” John M. Kirkwood, MD, and colleagues wrote in the poster. “Unfortunately, these statistical methods do not account for nonproportional hazards and the fact that some patients never experience relapse.”

READ THE ORIGINAL FULL ARTICLE

The post Dabrafenib plus trametinib improves relapse-free survival time in melanoma appeared first on Melanoma Research Victoria.

]]>
Circulating tumor DNA could help guide treatment of BRAF V600-mutant metastatic melanoma https://melanomaresearchvic.com.au/circulating-tumor-dna-could-help-guide-treatment-of-braf-v600-mutant-metastatic-melanoma Thu, 01 Apr 2021 05:54:20 +0000 https://melanomaresearchvic.com.au/?p=16555 Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant unresectable or metastatic melanoma, according to study results published in The Lancet Oncology.

The post Circulating tumor DNA could help guide treatment of BRAF V600-mutant metastatic melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Healio, February 2021

Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant unresectable or metastatic melanoma, according to study results published in The Lancet Oncology.

“Treatment of metastatic melanoma has made enormous strides within the past 10 years; however, we still lack validated, sensitive and specific blood-based biomarkers to predict and monitor treatment efficacy,” David Polsky, MD, PhD, Alfred W. Kopf professor of dermatologic oncology at NYU Langone Health, told Healio.

READ THE ORIGINAL FULL ARTICLE

The post Circulating tumor DNA could help guide treatment of BRAF V600-mutant metastatic melanoma appeared first on Melanoma Research Victoria.

]]>
Slick Woods, Who Rose From Homeless Teen to Become Rihanna’s Favorite Model, Says She Has Stopped Chemo For Melanoma https://melanomaresearchvic.com.au/slick-woods-who-rose-from-homeless-teen-to-become-rihannas-favorite-model-says-she-has-stopped-chemo-for-melanoma Thu, 01 Apr 2021 05:49:13 +0000 https://melanomaresearchvic.com.au/?p=16553 Slick Woods, born Simone Thomson, has decided to stop her treatment for stage three melanoma, which is an aggressive form of the disease and can be fatal.

The post Slick Woods, Who Rose From Homeless Teen to Become Rihanna’s Favorite Model, Says She Has Stopped Chemo For Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: survivornet, February 2021

Slick Woods, born Simone Thomson, has decided to stop her treatment for stage three melanoma, which is an aggressive form of the disease and can be fatal.

For someone going through cancer, the decision to stop treatment is excruciating and personal. For some, there is also a sense of empowerment after suffering.

READ THE ORIGINAL FULL ARTICLE

The post Slick Woods, Who Rose From Homeless Teen to Become Rihanna’s Favorite Model, Says She Has Stopped Chemo For Melanoma appeared first on Melanoma Research Victoria.

]]>
Gene-Based Blood Test for Melanoma Spread Evaluates Treatment Progress https://melanomaresearchvic.com.au/gene-based-blood-test-for-melanoma-spread-evaluates-treatment-progress Thu, 01 Apr 2021 05:41:09 +0000 https://melanomaresearchvic.com.au/?p=16551 A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in the late stages of one of the most aggressive forms of skin cancer, a new study finds.

The post Gene-Based Blood Test for Melanoma Spread Evaluates Treatment Progress appeared first on Melanoma Research Victoria.

]]>
Source: NYU Langone Health, February 2021

A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in the late stages of one of the most aggressive forms of skin cancer, a new study finds.

Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically or are unresectable.

READ THE ORIGINAL FULL ARTICLE

The post Gene-Based Blood Test for Melanoma Spread Evaluates Treatment Progress appeared first on Melanoma Research Victoria.

]]>
Dermoscopy helps differentiate benign melanocytic lesions vs. melanoma https://melanomaresearchvic.com.au/dermoscopy-helps-differentiate-benign-melanocytic-lesions-vs-melanoma Wed, 31 Mar 2021 04:46:32 +0000 https://melanomaresearchvic.com.au/?p=16548 Dermoscopy allows for thorough observation of morphologic features not visible to the naked eye in melanoma screening, according to a speaker at the South Beach Symposium Medical Dermatology Summit.

The post Dermoscopy helps differentiate benign melanocytic lesions vs. melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Healio, February 2021

Dermoscopy allows for thorough observation of morphologic features not visible to the naked eye in melanoma screening, according to a speaker at the South Beach Symposium Medical Dermatology Summit.

“[Dermoscopy] is a noninvasive diagnostic technique that has become very popular. It does allow for observation of features that are not visible to the naked eye using colors and structures,” David J. Goldberg, MD, JD, of Skin Laser & Surgery Specialists of New York and New Jersey and Icahn School of Medicine at Mount Sinai, said. “It does differentiate between melanocytic and non-melanocytic lesions as well as benign or malignant neoplasms.

READ THE ORIGINAL FULL ARTICLE

 

The post Dermoscopy helps differentiate benign melanocytic lesions vs. melanoma appeared first on Melanoma Research Victoria.

]]>
Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases https://melanomaresearchvic.com.au/circulating-tumor-dna-provides-prognostic-clues-in-advanced-braf-mutated-melanoma-cases Wed, 31 Mar 2021 04:23:13 +0000 https://melanomaresearchvic.com.au/?p=16545 In a new clinical validation study, an international team led by investigators at NYU Langone Health has demonstrated that BRAF gene mutations detected in cell-free circulating tumor DNA (ctDNA) can offer a window into treatment response and potential outcomes in individuals with melanoma.

The post Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases appeared first on Melanoma Research Victoria.

]]>
Source: genomeweb, February 2021

In a new clinical validation study, an international team led by investigators at NYU Langone Health has demonstrated that BRAF gene mutations detected in cell-free circulating tumor DNA (ctDNA) can offer a window into treatment response and potential outcomes in individuals with melanoma.

“Our findings suggest that levels of ctDNA may serve as a fast and reliable tool to gauge whether an anticancer medication is working,” senior author David Polsky, a pathology researcher at NYU Langone, said in a statement, noting that a blood test based on such ctDNA-based markers “could help support continuing the current treatment strategy or else encourage patients and physicians to consider other options.”

READ THE ORIGINAL FULL ARTICLE

The post Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases appeared first on Melanoma Research Victoria.

]]>
Radiotherapy may not improve outcomes in uveal melanoma with extraocular extension https://melanomaresearchvic.com.au/radiotherapy-may-not-improve-outcomes-in-uveal-melanoma-with-extraocular-extension Wed, 31 Mar 2021 04:10:39 +0000 https://melanomaresearchvic.com.au/?p=16543 There was no significant difference in survival in eyes that underwent enucleation for uveal melanoma with extraocular extension between postoperative orbital external beam radiotherapy vs. observation, according to a poster presentation.

The post Radiotherapy may not improve outcomes in uveal melanoma with extraocular extension appeared first on Melanoma Research Victoria.

]]>
Source: Healio, February 2021

There was no significant difference in survival in eyes that underwent enucleation for uveal melanoma with extraocular extension between postoperative orbital external beam radiotherapy vs. observation, according to a poster presentation.

“The purpose of the present study was to improve evidence-based management of patients with [extraocular extension] from [uveal melanoma] undergoing enucleation,” Kelsey A. Roelofs, MD, FRCSC, and colleagues wrote in the poster presented at the virtual American Society of Ophthalmic Plastic and Reconstructive Surgery annual meeting.

READ THE ORIGINAL FULL ARTICLE

The post Radiotherapy may not improve outcomes in uveal melanoma with extraocular extension appeared first on Melanoma Research Victoria.

]]>
Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size https://melanomaresearchvic.com.au/optimising-prediction-of-early-metastasis-free-survival-in-uveal-melanoma-using-a-four-category-model-incorporating-gene-expression-profile-and-tumour-size Thu, 25 Mar 2021 03:55:51 +0000 https://melanomaresearchvic.com.au/?p=16531 Since largest basal diameter (LBD) seems to have independent prognostic worth in uveal melanoma (UM), this topic is further studied herein among all patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019.

The post Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, February 2021

Since largest basal diameter (LBD) seems to have independent prognostic worth in uveal melanoma (UM), this topic is further studied herein among all patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019.

READ THE ORIGINAL FULL ARTICLE

The post Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size appeared first on Melanoma Research Victoria.

]]>